the goal of ambulatory total respiratory support for weeks to months as a bridge to lung transplant or lung recovery or, ultimately, as long-term support. Although extracorporeal membrane oxygenation (ECMO) has occasionally been used as a bridge to lung transplant, 1 it is labor intensive, complicated, limited to a few weeks, nonambulatory, and will not be discussed as an AL.
Long-term ambulatory artificial respiration strategies can be divided into partial support and full support (Figure 1 A-D) . Partial support involves gas exchange parallel to the native circulation. There are two types of partial support, and both are passively driven: For central partial support, a pulmonary artery to left atrium AL (PA-LA "pop-off" AL) is driven by the difference between mean pulmonary artery pressure and left atrial pressure; for peripheral partial support, mean systemic arterial pressure drives blood through a gas exchange device with return to a peripheral vein (arterial venous CO 2 removal or AVCO 2 R).
Full respiratory support requires complete capture of the desaturated pulmonary blood flow. In series strategies include passive diversion through a low resistance AL (PA-PA configuration) or pump powered bypass of the right ventricle (RA-PA). Both strategies have the AL in series with the native lungs, with return of blood to the distal pulmonary artery.
Full respiratory support in parallel to the native lungs requires all pulmonary artery blood diverted through an AL (with bypass of the lungs) and return of blood to the left atrium. The lung is the only organ in the body perfused with all the cardiac output after each pass through the heart. Because the lung is responsible for unique metabolic functions, including bioactive amine metabolism, 2 depriving lung blood flow results in a proportional decrease in metabolic function down to 10%, below which physiologic collapse occurs. 3 Severely decreased pulmonary blood flow also risks thrombosis of the pulmonary circulation.
Partial Respiratory Support

Peripheral Partial Support: Arterial Venous CO 2 Removal
During peripheral partial support (Figure 1A) , a systemic artery and vein are cannulated percutaneously and connected to a low resistance membrane gas exchange device. Blood flows of 1-2 L/min can provide total removal of CO 2 produced, allowing low frequency or near static (apneic) ventila-tion. The setup is pumpless, smaller, and less complex than ECMO and, therefore, much less labor intensive. Oxygenation is essentially uncoupled from CO 2 removal (but not completely, with partial peripheral oxygenation inversely proportional to the saturation of arterial blood entering the device). With CO 2 removal uncoupled from oxygenation, AVCO 2 R allows for gentle, low tidal volume ventilation of patients with adult respiratory distress syndrome (ARDS) or CO 2 retention syndromes without ventilator associated lung injury or the side effects of respiratory acidosis associated with permissive hypercapnia. 4 -6 AVCO 2 R also has been used for chronic obstructive pulmonary disease (COPD) exacerbations to decrease minute ventilation, patient anxiety from air hunger, and ventilator aggravated parenchymal air leak (authors' experience). Ambulatory AVCO 2 R for long-term use is being developed for patients with end-stage COPD marked by CO 2 retention. In an animal model of ambulatory AVCO 2 R, a polytetrafluoroethylene (PTFE) arterial venous loop (6 -8 mm) anastomosed in parallel to the peripheral (neck) circulation, similar to dialysis access, allows 800 mL/min and up to 2000 mL/min blood flow, respectively, through a low resistance membrane gas exchanger. 7 With sweep gas rates of 4:1 (6 mm PTFE) or 2:1 (8 mm PTFE), near whole body basal CO 2 production can be removed. Sweep gas may be room air because the only requirement is low CO 2 level. AVCO 2 R was initially developed as a bridge to recovery strategy to lower barotrauma and volutrauma in patients with ARDS; however, AVCO 2 R may have much wider application in an ambulatory configuration as a bridge to transplant or as an alternative to transplant (long-term palliation). The main attractiveness of AVCO 2 R is that it is simpler and less invasive than other forms of AL: No pump is needed, and access is through peripheral vessels. The minimal oxygen transfer is an obvious limitation of the technique.
Central Partial Support: Pulmonary Artery to Left Atrium Artificial Lung
Severe lung disease is often marked by transient or long standing pulmonary hypertension. A low resistance AL, with an inflow cannula anastomosed to the side of the pulmonary artery and outflow to the left atrium, allows for flow through the AL in competition with the pulmonary circulation. Flow is driven by the gradient between the mean pulmonary artery pressure minus the left atrial pressure. Because pulmonary artery pressures can vary widely and quickly depending on baseline and transient physiological states, blood flow likewise can range widely and unpredictably.
Because the PA-LA configuration (Figure 1B) offers an alternative route for blood to get from right ventricle to left atrium, it lowers right heart impedance. The lower the resistance in the AL, the higher the proportional flow will be through the AL, and the lower the overall right ventricular impedance. Using the MC3 prototype device ([MC3 Corporation, Ann Arbor, MI] known to have a 5 mm drop in pressure at 5 L flow bench testing) in healthy sheep, proportional flow through the device varied from 10% to 90% of right heart output, with an average of 47%. 8 The PA-LA configuration is designed for lung failure marked by pulmonary hypertension and right heart failure. A major concern is that during times of device malfunction or intolerance to systemic anticoagulation (anticoagulation is a presumed necessity), the device could not be removed with the remaining implanted cannulas reconnected to a shunt, or severe peripheral desaturation would result. Also, device implantation, malfunction, and change out could have some risk of systemic or cerebral embolization. To avoid these potential problems and to ensure complete oxygenation, the authors have pursued the pulmonary artery to pulmonary artery (PA-PA) configuration.
Full Respiratory Support
Pulmonary Artery to Pulmonary Artery Artificial Lung
The advantages of full blood diversion through an AL are as follows: (1) complete gas exchange; (2) device removal with replacement with a shunt during times of intolerance to anticoagulation (e.g., immediately after implant or if the patient has active bleeding); and (3) no risk of stroke during device malfunction or change out.
This configuration ( Figure 1C ) allows for full flow of right ventricular output through the AL, which results in complete oxygenation and CO 2 exchange. However, because the AL is in series with the lung bed, this high resistance configuration results in right heart strain. 9 Placement of the original "low resistance" MC3 prototype in this configuration resulted in a 50% incidence of immediate right heart failure in normal sheep. 10 The device was modified to further lower resistance and impedance by the addition of an inflow compliance chamber designed to accept the full right ventricular stroke volume without elastic expansion. These changes allowed a normal cardiac output and right atrial pressure. 11 The resultant paracorporeal AL tested in a LD-90 model of lung injury in sheep resulted in improved 5 day survival and lung wet to dry ratios for the artifical lung treated animals. 12 Oxygenated blood is a strong pulmonary vasodilator. 13 The authors have observed the vasodilatory effects of oxygenated blood leaving an AL to perfuse the lung bed in both healthy and lung injured ovine models. However, for an AL to be ready for clinical implantation, it should compensate for transient or fixed pulmonary hypertension. Pulmonary hypertension is present in approximately half of lung transplant candidates and frequently occurs during acute respiratory failure. To that end, the next modification of the MC3 prototype was shell encasement of the compliance chamber, converting from a passive container to an extracorporeal counterpulsation device. Connected to a standard intraaortic balloon pump (IABP) console, and triggered by a surface ECG, the chamber is actively collapsed in diastole, pushing blood against a closed pulmonic valve and out through the AL; in systole, the balloon expands, assisting right ventricular ejection. Bench and in vivo tests show ample capacity to address moderate pulmonary hypertension. 14 The assist can be completely optional, returning to a passive chamber when disconnected from the IABP console, which allows easier ambulation.
Implanting an AL in the PA-PA configuration is simple in sheep. They have a lengthy (6 cm) main pulmonary artery, with ample room for a proximal and distal end to side anastomosis and ligation of the intervening segment to divert all blood through the AL. Cardiopulmonary bypass is not required for implantation. Adult humans have only a 2.5-3 cm main pulmonary artery, which makes such an implant impractical. Potential alternatives include (1) dividing the pulmonary artery on bypass, with return of postoxygenator blood to the transected distal segment, or (2) anastomosing a graft to the side of the main pulmonary artery and ligating the main pulmonary artery distally, diverting all main PA blood into the device, with return to the right pulmonary artery. This is a similar setup to the Fontan operation in children, but with a unique problem: The greater curve of the ascending aorta, superior vena cava, and AL outflow graft all compete for roughly the same space. Unfortunately, neither option appears attractive for long-term implantation.
Right Atrium to Pulmonary Artery Artificial Lung
The anatomic limits of the short human PA have led some to pursue complete (or near complete) support via the right atrium to pulmonary artery (RA-PA) (Figure 1D) with an AL coupled to a pump. This configures the AL like a right ventricular assist device (RVAD) so that the blood leaves the right atrium, passes through a pump then the AL, and returns to the main pulmonary artery. Access is straightforward through a median sternotomy, and no cardiopulmonary bypass support is needed for implant or removal.
A prototype centrifugal pump with membrane fibers incorporated into the spinning disc is under development. This spinning membrane disc exchanges gasses while simultaneously generating forward flow. The active mixing delivers excellent gas exchange on a per membrane surface area basis. The prototype is designed for ambulation and easy change out.
Alternative strategies to an RA-PA AL could include separate components, that is, pulseless pumps (centrifugal or axial) connected to an AL or a pulsatile pump connected to a compliance chamber in series with an AL. Separation of pumping function from gas exchange, with separate components, has the advantage of continued pump function during periods of intolerance to anticoagulation (an RVAD can run for days without anticoagulation). Elective AL interposition can then be performed when the patient tolerates the higher level of anticoagulation required. However, separating the pump from the AL would be bulkier than a combined pump/AL.
Clinical Role
The AL initially will focus on relatively short-term (a few weeks) ambulatory gas exchange bridging to transplantation. Currently, the lung transplant waiting list is a single tiered system; organs are allocated based on "time on the list" (within the constraints of compatible blood type and size). Average waiting time is approximately 300 days. However, a recent survey of lung transplant program directors showed a favorable response to creating a special status for patients on mechanical assist. 15 The United Network for Organ Sharing, the administrative body in charge of organ allocation in the United States, is considering a far more complex lung waiting list, dividing patients into four broad categories of lung disease, with priority computed by formulas estimating risk of dying without a transplant versus risk of perioperative death. 16 The future availability of an AL was not considered in the proposed United Network for Organ Sharing plan.
The Future
The AL as a bridging device will likely remain paracorporeal and ambulatory, with true implantability many years away. Bulky size, gas inflow and outflow requirements, possible pump requirements, gas leak, and inevitable weeping/clotting within hollow fibers all make paracorporeal positioning desirable for easy device servicing and change out. Differing roles will evolve for the different modes of support. Peripheral, partial gas exchange, passively driven by mean arterial pressure (AVCO 2 R) is simple and likely will provide palliation to patients with end-stage COPD characterized by CO 2 retention and markedly increased work of breathing. Central partial support (PA-LA) is best suited for severe pulmonary hypertension. Central full support via the PA-PA route will need to overcome the challenges of the short human main pulmonary artery. As centrifugal and axial blood pumps become more available for clinical practice, these will likely be mated to gas exchange devices allowing full or near full gas exchange via the right atrium to pulmonary artery. Component RA-PA based circuits initially should be the most versatile, easily inserted and removed, and useful for both acute and chronic respiratory failure situations.
